Log in with your email address username.


[Comment] Neoadjuvant chemotherapy for ovarian cancer: do we have enough evidence?

Although primary cytoreductive surgery followed by chemotherapy has been the standard treatment for advanced ovarian cancer for many years, neoadjuvant chemotherapy followed by interval debulking surgery has emerged as a new alternative treatment of advanced ovarian cancer after the EORTC-NCIC trial.1 In The Lancet, Sean Kehoe and colleagues2 show the benefits of using neoadjuvant chemotherapy for patients with advanced ovarian cancer. In a comparison of primary surgery versus primary chemotherapy in 552 patients with advanced ovarian cancer, they showed that primary chemotherapy was not only equally effective but also a substantially safer strategy.